We identified 5 RCTs of patients receiving BRAF and MEK inhibitor therapy compared with patients receiving BRAF inhibitor monotherapy.6,9,10,17,27 A total of 2317 patients with melanoma were included. This evidence concerns the gene MAP2K7 and melanoma.